



CSRC Think Tank: Detection, Assessment and Risk Mitigation of Cardiac Safety Signals in Oncology Drug Development

Session I: Translational Medicine and Non-clinical Signals of Potential Cardiac Toxicity

Translational Medicine Group Members

Luana Pesco Koplowitz, MD, PhD - *Chairperson*

(DUCKS FLATS Pharma)

Gary Gintant, PhD (Abbvie)

Baichun Yang, PhD (FDA)

Ksenia Blinova, PhD (FDA)

Paul Burrige, PhD (Northwestern University)

Matthew Brock, PhD (Genentech)

TRANSLATIONAL MEDICINE: Dependent on Multiple Factors (i.e. Biomarkers)

Definition: A defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions

Types: Molecular, histologic, radiographic, or physiologic characteristics

BIOMARKERS IN DRUG DEVELOPMENT

